课题基金 / 基金详情

Covid-19 PPE - PeRSo Powered Air-Purifying Respirator (PAPR)

Covid-19 PPE - PeRSo Powered Air-Purifying Respirator (PAPR)
Covid-19 PPE - PerSo 动力空气净化呼吸器 (PAPR)
批准号:
58010
负责人:
金额:
$6.36万
依托单位:
依托单位国家:
英国
项目类别:
Feasibility Studies
财政年份:
2020
资助国家:
英国
项目状态:
已结题
起止时间:
2020 至 --
关键词:

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
我们的项目旨在大量开发和制造一种价格实惠、可重复使用的带罩和集成面罩的电动空气净化呼吸器(PERSO),使NHS一线工作人员和医护人员在治疗患者的同时保持安全、有效和舒适。这个想法是为了让Perso补充甚至取代目前使用的外科口罩或呼吸器口罩(N95/FFP3),这些口罩在全球范围内供不应求,供应链上仍存在重大挑战。Perso将为用户在污染环境中工作时提供个人保护。该人员将通过呼吸管和呼吸器罩为用户提供干净的空气,以便用户在当前的新冠肺炎大流行中安全、自信、舒适、有效地照顾患者。通过这个项目,我们可以扩展到大量生产Perso,这样他们就成为一线工作人员的标准问题。我们的NHS和一线工作人员正在令人难以置信地努力工作,在新冠肺炎大流行期间拯救生命,我们相信这款产品可以帮助他们在我们最需要的时候保持安全和弹性。
英文摘要
Our project aims to develop and manufacture at high volumes an affordable and reusable powered air-purified respirator with hood and integrated mask (the PeRSo) which will enable frontline NHS staff and healthcare workers to remain safe, work effectively and in comfort whilst treating patients. The idea is for the PeRSo to supplement and even replace the current use of surgical masks or respirator masks (N95/FFP3) which are in short supply globally and with significant challenges continuing in the supply chain.The PeRSo will provide personal protection to the user when working in a contaminated environment. The PeRSo will provide clean air to the user via breathing tube and respirator hood so that the user can safely, confidently, comfortably and effectively look after patients in the current Covid-19 pandemic. Through this project we can scale to a high-volume manufacture of PeRSo so they become standard issue to staff on the frontline.Our NHS & frontline staff are working incredibly hard to save lives during the Covid-19 pandemic and we believe this product can help them stay safe and resilient when we need them most.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
芽孢杆菌TR19-1对魔芋腐皮镰刀菌拮抗机理研究
1H/19F多核MRI术中可视化免疫抑制巨噬细胞定位脑胶质瘤浸润边界
CD19/BCMA双靶向CAR-NK细胞治疗难治性SLE:作用机制与临床前转化研究
  • 批准号:
    2026JJ81339
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    谢希
  • 依托单位:
ATPIF1调节线粒体膜电位影响靶向CD19 CAR-T细胞抗肿瘤活性的作用及机制
  • 批准号:
    2026JJ80001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    钟根深
  • 依托单位: